Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Current Quarter	$NA	Next Quarter	$NA
Current Year	$NA	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	-1.3%	Target Price	$6.00
Consensus	Buy	Upside	+426.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CTXR	$1.14	+15.15%	1.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CTXR	$1.14	+15.2%	1.18M
3
4
5
6

CTXR

CTXR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Citius Pharmaceuticals Inc. Data in Excel

Get Citius Pharmaceuticals Inc. Data in Excel